New report features Noctura treatment

Noctura 400 has been featured in a newly published Primary Care Special Report titled Improving the Prevention and Treatment of Diabetic Retinopathy and Diabetic Macular Oedema, which covers a range of articles about detection, prevention and new treatment options for diabetic eye disease. These reports are aimed at healthcare professionals and contain subject specific clinical […]

Renaissance man – North East Times

Richard Kirk is CEO of a County Durham-based medical technology company that has developed a non-invasive treatment to prevent, treat and even reverse blindness in diabetics – potentially saving the NHS hundreds of millions of pounds. His career can best be described as unorthodox, as Alison Cowie discovers. Richard Kirk, CEO and chief technical officer […]

Noctura 400 in France

Richard Kirk, PolyPhotonix, attended the Retina Lyon conference in France, held from 9th-10th December 2016. Lyon and its Festival of Lights served as the framework for the 2016 edition of the annual conference and brought together internationally renowned speakers. This conference was a perfect setting for presentation of Noctura 400 to scientific and medical professionals […]

NETPark company says patients are flying in from US to use Noctura 400 mask

A County Durham firm behind revolutionary blindness treatment is plotting further global expansion as strong transatlantic demand bolsters its market standing, The Northern Echo can reveal. PolyPhotonix says patients are flying in from the US to use its Noctura 400 mask. The eye cover, developed thanks to £14m of taxpayers’ funding, delivers light therapy to […]

Diabetes and sight loss link highlighted during awareness week

Worrying statistics reporting that over 50% of diabetics have experienced a sight-related complication associated to their diabetes have been released ahead of Diabetes Week (12–18 June). The survey, performed by healthcare marketing and communications agency Onyx Health, revealed that despite the known associated risk of sight loss and diabetes, such as retinopathy, 17% of diabetes […]